Zymeworks Inc

149 articles with Zymeworks Inc

• Zanidatamab Data Highlight Durable Antitumor Activity in HER2‑Expressing Biliary Tract and Gastroesophageal Cancers at ASCO Gastrointestinal Cancers Symposium

  1/15/2021

  Durable Responses Observed in Refractory Biliary Tract Cancer (BTC) and Gastroesophageal (GEA) Cancers Enrollment Continues for Zanidatamab Global Pivotal Trial in BTC; Global Pivotal Trial in First-Line GEA Slated to Open in Mid-2021

• Zymeworks Highlights 2020 Achievements and Announces Corporate Priorities

  1/11/2021

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2020 and updated its corporate priorities.

• Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

  12/10/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021.

• 

  FDA Works to Get New Drugs to Patients Faster with Multiple Approvals This Week

  12/2/2020

  The FDA uses special designations to get new, breakthrough treatments to patients in the greatest need.

• Zymeworks Announces Expansion of Zanidatamab Pivotal Trial in HER2-Amplified Biliary Tract Cancer in Asia in Collaboration With BeiGene

  12/1/2020

  Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in South Korea in a pivotal, single-arm clinical trial of zanidatamab (formerly ZW25) monotherapy in patients with advanced or metastatic HER2-amplified biliary tract cancer (BTC)

• Zymeworks Receives FDA Breakthrough Therapy Designation for HER2-Targeted Bispecific Antibody Zanidatamab in Patients with Biliary Tract Cancer

  11/30/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for zanidatamab in patients with previously-treated HER2 gene-amplified biliary tract cancer (BTC).

• Zymeworks Receives Orphan Drug Designation From the European Commission for HER2-Targeted Bispecific Antibody Zanidatamab in Patients With Gastric Cancer

  11/19/2020

  Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the European Commission (EC) has granted Orphan Drug designation for zanidatamab, the company’s investigational HER2-targeted bispecific antibody, in patients with gastric cancer.

• Zymeworks and ALX Oncology Announce Clinical Collaboration Evaluating Zanidatamab with the CD47 Blocker ALX148 in Patients with Advanced HER2‑Expressing Breast Cancer

  11/16/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX Oncology Holdings Inc. (NASDAQ: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced they have entered into a clinical collaboration to evaluate the combination of Zymeworks’ zanidatamab (formerly ZW25)

• Zymeworks to Present at Upcoming Investor Conferences - Nov 10, 2020

  11/10/2020

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that management will participate in four upcoming virtual investor conferences.

• Zymeworks Reports 2020 Third Quarter Financial Results

  11/3/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the quarter ended September 30, 2020.

• ImmunoPrecise Announces New Multi-Specific SARS-CoV-2 Antibody Collaboration with Zymeworks

  9/17/2020

   IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) (FSE: TQB2), a leader in full-service, therapeutic antibody discovery and development,  announce a research collaboration with Zymeworks Inc., giving ImmunoPrecise access to  Zymeworks' Azymetric™ and EFECT™ platforms for the

• Zymeworks Corporate Update Webcast and Conference Call Summary

  7/8/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today hosted a webcast and conference call highlighting its progress and key accomplishments in the first half of 2020.

• Zymeworks Announces New Multispecific Antibody Collaboration with Merck

  7/8/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it and longtime partner, Merck (known as MSD outside the US and Canada) have signed a new license agreement granting Merck the right to develop additional multispecific antibody therapeutic candidates using Zymeworks’ Azymetric™ and EFECT™ platforms.

• Zymeworks Announces Corporate Update Webcast and Conference Call

  6/30/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that it will host a webcast and conference call to discuss progress on its corporate priorities and upcoming catalysts. Webcast and Conference Call Details Zymeworks will host a webcast and conference call on Wednesday, July 8, 2020 at 4:30pm ET (1:30pm PT). Interes

• Zymeworks to Present at the Jefferies 2020 Virtual Healthcare Conference

  5/28/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Jefferies 2020 Virtual Healthcare Conference taking place June 2-4, 2020. The Company’s presentation will be on Thursday, June 4, 2020 at 2:30 p.m. ET. Interested parties can access a live webcast of the presentation via a link

• Zymeworks Announces Election of Directors and Voting Results from Shareholder Meeting - May 08, 2020

  5/8/2020

  Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, is pleased to announce the detailed voting results on the items of business considered at its Annual General Meeting of Shareholders held on May 7, 2020.

• Zymeworks Reports 2020 First Quarter Financial Results

  5/7/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2020.

• Zymeworks Announces First Patient Dosed in Phase 1b/2 Trial of ZW25 in First-Line HER2-Positive Breast Cancer and Gastroesophageal Adenocarcinoma Conducted by BeiGene

  4/1/2020

  Zymeworks Inc. announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluating Zymeworks’ HER2-targeted bispecific antibody ZW25 in combination with chemotherapy as a first-line treatment for patients with metastatic HER2-positive breast cancer and in combination with chemotherapy and BeiGene’s PD-1-targeted antibody tislelizumab as a first-line treatment for patients with metastatic HER2-positive gastroesophageal adenocarcinoma.

• Zymeworks Appoints Dr. Kelvin Neu to the Board of Directors

  3/16/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.

•  Zymeworks Reports 2019 Year-End Financial Results

  3/2/2020

  Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019. “